Program
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine
Also written as “Infanrix hexa”, “DTPa-HBV-IPV/Hib” and “Infanrix™ hexa”.
Its studies are mostly in Hepatitis B · Diphtheria · Streptococcal Infections · Poliomyelitis · Meningococcal Infections, led by 4 companies.
Drug pageDiphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 230 open or running | phase 4since Jan 29, 2008 | Sep 13, 2005 | none ahead |
| Pfizer | 21 open or running | phase 4since Feb 17, 2006 | Feb 17, 2006 | Nov 6, 2028phase 3 · NCT07160244 |
| Merckits history only | 10 open or running | phase 3since Feb 5, 2007 | Feb 5, 2007 | none ahead |
| Sanofiits history only | 11 open or running | phase 2since Oct 16, 2024 | Oct 16, 2024 | May 17, 2027phase 2 · NCT06647407 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 17, 2006First study: phase 4 study in FeverFirst studyNCT00294294 · 300 enrolled
- Aug 14, 2025Phase 3 study in HealthyNCT07160244 · 6,000 planned · United States, Argentina, Brazil and more
Ahead
- Nov 6, 2028Primary completion: phase 3 study in HealthyNCT07160244
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 2 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07160244Healthy · United States, Argentina, Brazil and more | 3 | Recruiting | Nov 6, 2028 | 6,000 |
| NCT00294294Fever | 4 | Completed | Dec 2006 | 300 |
How it is read
Names in the registry
- “Infanrix hexa”, 10 entries
- “DTPa-HBV-IPV/Hib”, 3 entries
- “Infanrix™ hexa”, 3 entries
- “Infanrix Hexa”, 2 entries
- “DTPa-HBV-IPV/Hib (Infanrix hexa™)”, 2 entries
Conditions, from the studies’ own filings
- Hepatitis B, 8 studies
- Diphtheria, 3 studies
- Streptococcal Infections, 3 studies
- Poliomyelitis, 3 studies
- Meningococcal Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.